126 related articles for article (PubMed ID: 15225831)
1. Anti-tumor activity of calcitriol: pre-clinical and clinical studies.
Trump DL; Hershberger PA; Bernardi RJ; Ahmed S; Muindi J; Fakih M; Yu WD; Johnson CS
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):519-26. PubMed ID: 15225831
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
[TBL] [Abstract][Full Text] [Related]
3. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model.
Ahmed S; Johnson CS; Rueger RM; Trump DL
J Urol; 2002 Aug; 168(2):756-61. PubMed ID: 12131364
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D-related therapies in prostate cancer.
Johnson CS; Hershberger PA; Trump DL
Cancer Metastasis Rev; 2002; 21(2):147-58. PubMed ID: 12465754
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer.
Trump DL; Potter DM; Muindi J; Brufsky A; Johnson CS
Cancer; 2006 May; 106(10):2136-42. PubMed ID: 16598750
[TBL] [Abstract][Full Text] [Related]
6. The antitumor efficacy of calcitriol: preclinical studies.
Johnson CS; Muindi JR; Hershberger PA; Trump DL
Anticancer Res; 2006; 26(4A):2543-9. PubMed ID: 16886662
[TBL] [Abstract][Full Text] [Related]
7. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.
Smith DC; Johnson CS; Freeman CC; Muindi J; Wilson JW; Trump DL
Clin Cancer Res; 1999 Jun; 5(6):1339-45. PubMed ID: 10389917
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system.
Light BW; Yu WD; McElwain MC; Russell DM; Trump DL; Johnson CS
Cancer Res; 1997 Sep; 57(17):3759-64. PubMed ID: 9288784
[TBL] [Abstract][Full Text] [Related]
9. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D receptor: a potential target for intervention.
Johnson CS; Hershberger PA; Bernardi RJ; Mcguire TF; Trump DL
Urology; 2002 Sep; 60(3 Suppl 1):123-30; discussion 130-1. PubMed ID: 12231068
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191).
Wietrzyk J; Pełczyńska M; Madej J; Dzimira S; Kuśnierczyk H; Kutner A; Szelejewski W; Opolski A
Steroids; 2004 Sep; 69(10):629-35. PubMed ID: 15465107
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
15. Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells.
Bonaccorsi L; Marchiani S; Ferruzzi P; Muratori M; Crescioli C; Forti G; Maggi M; Baldi E
Steroids; 2006 Apr; 71(4):304-9. PubMed ID: 16289173
[TBL] [Abstract][Full Text] [Related]
16. Calcitriol in the treatment of prostate cancer.
Beer TM; Myrthue A
Anticancer Res; 2006; 26(4A):2647-51. PubMed ID: 16886675
[TBL] [Abstract][Full Text] [Related]
17. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
18. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S
Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160
[TBL] [Abstract][Full Text] [Related]
20. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
